Last reviewed · How we verify
IMO-2125
IMO-2125 is a synthetic oligonucleotide that acts as a TLR9 agonist, stimulating the innate immune system.
IMO-2125 is a synthetic oligonucleotide that acts as a TLR9 agonist, stimulating the innate immune system. Used for Advanced solid tumors.
At a glance
| Generic name | IMO-2125 |
|---|---|
| Also known as | tilsotolimod (tilso) |
| Sponsor | Idera Pharmaceuticals, Inc. |
| Drug class | TLR9 agonist |
| Target | TLR9 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By activating TLR9, IMO-2125 induces the production of cytokines and enhances the activity of natural killer cells and dendritic cells, which can lead to an antitumor immune response.
Approved indications
- Advanced solid tumors
Common side effects
- Injection site reaction
- Fatigue
Key clinical trials
- A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (PHASE3)
- A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma (PHASE2)
- Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) (PHASE2)
- A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma (PHASE2)
- A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (PHASE1)
- Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients (PHASE1)
- Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |